| Pharmacologic and clinical evaluation of posaconazole JN Moore, JR Healy, WK Kraft Expert review of clinical pharmacology 8 (3), 321-334, 2015 | 68 | 2015 |
| A population pharmacokinetic model for vancomycin in adult patients receiving extracorporeal membrane oxygenation therapy JN Moore, JR Healy, BN Thoma, MM Peahota, M Ahamadi, L Schmidt, ... CPT: pharmacometrics & systems pharmacology 5 (9), 495-502, 2016 | 39 | 2016 |
| Galectin‐1 is essential for the induction of MOG35–55‐based intravenous tolerance in experimental autoimmune encephalomyelitis ER Mari, J Rasouli, B Ciric, JN Moore, JR Conejo‐Garcia, N Rajasagi, ... European journal of immunology 46 (7), 1783-1796, 2016 | 28 | 2016 |
| Subdermal ultrasound contrast agent injection for sentinel lymph node identification: an analysis of safety and contrast agent dose in healthy volunteers P Machado, M Stanczak, JB Liu, JN Moore, JR Eisenbrey, L Needleman, ... Journal of Ultrasound in Medicine 37 (7), 1611-1620, 2018 | 26 | 2018 |
| The pharmacokinetics and pharmacodynamics of buprenorphine in neonatal abstinence syndrome JN Moore, MR Gastonguay, CM Ng, SC Adeniyi‐Jones, DE Moody, ... Clinical Pharmacology & Therapeutics 103 (6), 1029-1037, 2018 | 24 | 2018 |
| Induction of peripheral tolerance in ongoing autoimmune inflammation requires interleukin 27 signaling in dendritic cells R Thomé, JN Moore, ER Mari, J Rasouli, D Hwang, S Yoshimura, B Ciric, ... Frontiers in Immunology 8, 1392, 2017 | 24 | 2017 |
| Mechanisms of immunological tolerance in central nervous system inflammatory demyelination ER Mari, JN Moore, GX Zhang, A Rostami Clinical and Experimental Neuroimmunology 6 (3), 264-274, 2015 | 14 | 2015 |
| Assessing CYP 2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition P Duan, F Wu, JN Moore, J Fisher, V Crentsil, D Gonzalez, L Zhang, ... CPT: Pharmacometrics & Systems Pharmacology 8 (3), 158-166, 2019 | 13 | 2019 |
| FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs E O˘Shaughnessy, Y Yasinskaya, C Dixon, K Higgins, J Moore, ... Clinical Infectious Diseases 74 (11), 2061-2066, 2022 | 9 | 2022 |
| A regulatory review approach for evaluation of micafungin for treatment of neonatal candidiasis G Taormina, R Gopinath, J Moore, Y Yasinskaya, P Colangelo, ... Clinical Infectious Diseases 73 (12), 2335-2340, 2021 | 9 | 2021 |
| Neonatal safety information reported to the FDA during drug development studies D Avant, G Baer, J Moore, P Zheng, A Sorbello, R Ariagno, L Yao, ... Therapeutic innovation & regulatory science 52 (1), 100-108, 2018 | 8 | 2018 |
| FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2-Positive RAS Wild-Type … SJ Casak, MN Horiba, M Yuan, J Cheng, SJ Lemery, YL Shen, W Fu, ... Clinical Cancer Research 29 (21), 4326-4330, 2023 | 6 | 2023 |
| A population pharmacokinetic model for vancomycin in adult patients receiving extracorporeal membrane oxygenation therapy. CPT Pharmacometrics Syst Pharmacol. 2016 JN Moore, JR Healy, BN Thoma, MM Peahota, M Ahamadi, L Schmidt, ... | 5 | |
| Diversity in clinical pharmacology: a call to action K Brown, S Etrouth, P Jayachandran, J Moore, A Oni‐Orisan, L Vasist, ... Clinical Pharmacology & Therapeutics 113 (3), 483-485, 2023 | 4 | 2023 |
| Could Postnatal Age–Related Uridine Diphosphate Glucuronic Acid Be a Rate‐Limiting Factor in the Metabolism of Morphine During the First Week of Life? T Liu, TR Lewis, JN Moore, WK Kraft, EB Gauda, D Sartori, DE Moody, ... CPT: Pharmacometrics & Systems Pharmacology 8 (7), 469-477, 2019 | 4 | 2019 |
| Food and Drug Administration Public Workshop Summary—Development Considerations of Antifungal Drugs to Address Unmet Medical Need Y Yasinskaya, S Bala, U Waack, C Dixon, K Higgins, JN Moore, CJ Jjingo, ... Clinical Infectious Diseases 77 (3), 380-387, 2023 | 2 | 2023 |
| Animal pharmacokinetics/pharmacodynamics (PK/PD) infection models for clinical development of antibacterial drugs: lessons from selected cases JN Moore, L Poon, S Pahwa, T Bensman, X Wei, ZY Danielsen, S Jang Journal of Antimicrobial Chemotherapy 78 (6), 1337-1343, 2023 | 2 | 2023 |
| Population pharmacokinetic and pharmacodynamic analysis of buprenorphine for the treatment of neonatal abstinence syndrome N Jason, M Gastonguay, MD Adeniyi-Jones, C Susan, DE Moody, ... | 2 | 2017 |
| Genomic signatures: gene expression profiles for autoimmune diseases are distinct and distinguishable from the normal immune response. K Maas, J Moore, J Parker, A Slater, S Chan, N Olsen, T Aune ARTHRITIS AND RHEUMATISM 44 (9), S398-S398, 2001 | 2 | 2001 |
| Semimechanistic Modeling of Eravacycline Pharmacodynamics Using In Vitro Time-Kill Data with MIC Incorporated in an Adaptive Resistance Function K Nguyen, TJ Bensman, X Wei, JN Moore Antimicrobial Agents and Chemotherapy 64 (9), 10.1128/aac. 01308-20, 2020 | 1 | 2020 |
